[{"data":1,"prerenderedAt":238},["ShallowReactive",2],{"drug-riociguat":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":66,"contraindications":94,"warnings":130,"renal":145,"monitoring":146,"interactions":147,"review":148,"examples":151,"atc":157,"iran":159,"usApproval":171,"links":177,"populations":193},"riociguat",1,{"fa":7,"en":8},"ریوسیگوات","Riociguat","cardiovascular",{"fa":11,"en":12},"محرک گوانیلات سیکلاز محلول","Soluble guanylate cyclase stimulator",[14],{"name":15,"market":16},"Adempas","US",[18,19,7],"adempas","ادمپاس",[21,35,42,50,58],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-0-5","tablet","oral","0.5 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},0.5,"mg",false,[16],[32],{"source":33,"section":34},"fda-adempas","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":39,"refs":40},"tab-1","1 mg tablet",{"amount":5,"unit":28,"perUnit":23,"scored":29},[16],[41],{"source":33,"section":34},{"id":43,"form":23,"route":24,"label":44,"concentration":45,"markets":47,"refs":48},"tab-1-5","1.5 mg tablet",{"amount":46,"unit":28,"perUnit":23,"scored":29},1.5,[16],[49],{"source":33,"section":34},{"id":51,"form":23,"route":24,"label":52,"concentration":53,"markets":55,"refs":56},"tab-2","2 mg tablet",{"amount":54,"unit":28,"perUnit":23,"scored":29},2,[16],[57],{"source":33,"section":34},{"id":59,"form":23,"route":24,"label":60,"concentration":61,"markets":63,"refs":64},"tab-2-5","2.5 mg tablet",{"amount":62,"unit":28,"perUnit":23,"scored":29},2.5,[16],[65],{"source":33,"section":34},[67],{"id":68,"disease":69,"label":70,"population":73,"type":77,"unit":28,"dose":78,"refs":80,"notes":83},"pah","pulmonary-arterial-hypertension",{"fa":71,"en":72},"PAH و CTEPH بزرگسال — شروع ۱ mg سه بار در روز؛ هر ۲ هفته ۰٫۵ mg افزایش تا حداکثر ۲٫۵ mg سه بار","PAH and CTEPH, adults — start 1 mg three times daily; increase by 0.5 mg every 2 weeks to max 2.5 mg three times daily",{"minAge":74},{"value":75,"unit":76},18,"year","fixed",{"perDose":5,"perDoseMax":62,"dosesPerDay":79},3,[81],{"source":33,"section":82},"2.1",[84],{"text":85,"refs":88},{"fa":86,"en":87},"افزایش فقط اگر فشار سیستولیک بالای ۹۵ و بدون علائم افت فشار. شروع ۰٫۵ mg در خطر افت فشار یا با مهارکننده‌های قوی CYP\u002FP-gp. سیلدنافیل ۲۴ و تادالافیل ۴۸ ساعت قبل قطع شوند.","Increase only if systolic BP stays >95 mmHg without hypotension. Start 0.5 mg if at risk of hypotension or with strong CYP\u002FP-gp inhibitors. Stop sildenafil 24 h and tadalafil 48 h before.",[89,90,92],{"source":33,"section":82},{"source":33,"section":91},"2.5",{"source":33,"section":93},"2.6",[95,104,112,122],{"id":96,"severity":97,"text":98,"refs":101},"preg","block",{"fa":99,"en":100},"بارداری.","Pregnancy.",[102],{"source":33,"section":103},"4.1",{"id":105,"severity":97,"text":106,"refs":109},"nitrates",{"fa":107,"en":108},"نیترات‌ها یا دهنده‌های نیتریک اکسید به هر شکل.","Nitrates or nitric oxide donors in any form.",[110],{"source":33,"section":111},"4.2",{"id":113,"severity":97,"text":114,"refs":117},"pde5",{"fa":115,"en":116},"مهارکننده‌های PDE-5 (سیلدنافیل، تادالافیل، واردنافیل) یا غیراختصاصی (دی‌پیریدامول، تئوفیلین)؛ سایر محرک‌های sGC.","PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) or non-specific PDE inhibitors (dipyridamole, theophylline); other sGC stimulators.",[118,120],{"source":33,"section":119},"4.3",{"source":33,"section":121},"4.4",{"id":123,"severity":97,"text":124,"refs":127},"phiip",{"fa":125,"en":126},"فشار ریوی ناشی از پنومونی‌های بینابینی ایدیوپاتیک (PH-IIP).","Pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP).",[128],{"source":33,"section":129},"4.5",[131,138],{"text":132,"refs":135},{"fa":133,"en":134},"هشدار جعبه‌ای: سمیت جنینی — در بارداری منع مصرف؛ پیش از شروع و ماهانه تست بارداری، پیشگیری مؤثر تا ۱ ماه پس از قطع (برنامه REMS).","Boxed warning: embryo-fetal toxicity — contraindicated in pregnancy; pregnancy test before and monthly, effective contraception until 1 month after stopping (REMS).",[136],{"source":33,"section":137},"Boxed Warning",{"text":139,"refs":142},{"fa":140,"en":141},"افت فشار؛ خونریزی (شامل هموپتیزی)؛ ادم ریه با بیماری انسدادی وریدهای ریه.","Hypotension; bleeding (including haemoptysis); pulmonary oedema with veno-occlusive disease.",[143],{"source":33,"section":144},"5",[],[],[],{"status":149,"reviewer":150,"date":150},"unverified",null,[152],{"regimen":68,"formulation":36,"input":153,"expect":156},{"ageYears":154,"weightKg":155},55,70,{"perDose":5,"tabletsPerDoseRounded":5},[158],"C02KX05",{"status":160,"forms":161,"refs":166},"registered",[162],{"code":163,"en":164,"fa":165},"52716","RIOCIGUAT TABLET ORAL 1 mg","قرص ریوسیگوات ۱ میلی‌گرم",[167],{"source":168,"section":169,"url":170},"darooyab-generic","G-5522\u002FRiociguat","https:\u002F\u002Fwww.darooyab.ir\u002FG-5522\u002FRiociguat",{"kind":172,"refs":173,"id":176},"NDA",[174],{"source":33,"section":175},"SPL approval \u002F marketing category","NDA204819",[178,181,185,188,191],{"kind":179,"url":180,"label":176},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=204819",{"kind":182,"url":183,"label":184},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=7b57509a-3d5d-41d4-8fed-1471e26372a3","FDA Adempas",{"kind":186,"url":187,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa615005.html",{"kind":189,"url":190,"label":158},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=C02KX05",{"kind":192,"url":170,"label":8},"darooyab",{"pregnancy":194,"lactation":203,"pediatric":212,"geriatric":221,"reproductive":230},{"level":195,"text":196,"quote":199,"refs":200},"contraindicated",{"fa":197,"en":198},"برچسب: در بارداری منع مصرف دارد.","Label: contraindicated in pregnancy.","( 4.4 , 7.1 ) • Pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP) ( 4.5 ) 4.1 Pregnancy Use of Adempas is contraindicated in patients who are pregnant [see Warnings and Precautions (5.1) , Use in Specific Populations ( 8.1 )] . 4.2 Nitrates and Nitric Oxide Donors Co-administration of …",[201],{"source":33,"section":202},"4",{"level":204,"text":205,"quote":208,"refs":209},"avoid",{"fa":206,"en":207},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Because of the potential for serious adverse reactions from Adempas, such as hypotension, in breastfed infants, advise women not to breastfeed during treatment with Adempas.",[210],{"source":33,"section":211},"8.2",{"level":213,"text":214,"quote":217,"refs":218},"not-established",{"fa":215,"en":216},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness of Adempas in pediatric patients have not been established [see Nonclinical Toxicology (13.2) ] .",[219],{"source":33,"section":220},"8.4",{"level":222,"text":223,"quote":226,"refs":227},"caution",{"fa":224,"en":225},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Of the total number of subjects in clinical studies of Adempas, 23% were 65 and over, and 6% were 75 and over [see Clinical Studies (14) ].",[228],{"source":33,"section":229},"8.5",{"level":222,"text":231,"quote":234,"refs":235},{"fa":232,"en":233},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Females Female patients of reproductive potential should use effective contraception prior to initiation of treatment, during treatment with Adempas and for 1 month after treatment with Adempas to prevent pregnancy [see Boxed Warning ].",[236],{"source":33,"section":237},"8.3",1792444421162]